Onyx Healthcare Inc

Onyx Healthcare Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.19 and a current ratio of 2.17, indicating strong liquidity relative to its liabilities. However, the company reported negative net cash after subtracting total debt, signaling potential liquidity constraints despite its otherwise robust balance sheet. Free cash flow was negative at -35.3 million TWD, driven by capital expenditures of -14.3 million TWD, suggesting ongoing investment in operational capacity. Profitability metrics show a return on equity of 7.14% and a return on assets of 5.21%, both below the industry median for Advanced Medical Equipment & Technology firms. Gross profit of 434.0 million TWD on 1.31 billion TWD in revenue yields a 33.0% margin, but operating income of 52.3 million TWD reflects a 4.0% margin, indicating pressure from operating expenses. Net income of 112.1 million TWD translates to a 8.5% net margin, which is modest for a capital-light healthcare equipment firm. The company's revenue is distributed across three segments: Europe, Americas, and Others. No segment-specific revenue figures are disclosed, but the "Others" category may include Asia-Pacific markets. Given the lack of geographic breakdown, it is unclear whether the company is overexposed to any single region. Onyx Healthcare Inc reported revenue of 1.31 billion TWD in the latest period, with a year-over-year growth rate of 10.4% based on analyst estimates of 1.48 billion TWD. The company is projected to maintain moderate growth in the next fiscal year, with no significant acceleration in revenue or margin expansion expected. Risk factors include liquidity constraints due to negative net cash and the potential for dilution, though the risk is currently assessed as low. No recent equity issuance or ATM programs are disclosed, and the company has not issued shares at a discount to market value in the past 12 months. The absence of a detailed 10-K filing or recent earnings call transcripts limits visibility into management's strategic direction and risk mitigation plans. Recent events include the publication of the latest financial snapshot and analyst estimates, but no material corporate actions or regulatory changes have been disclosed in the past 90 days. The company's focus on medical-use computers and related components remains unchanged, with no new product lines or market expansions announced.